Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma
| Autor: | Sjoukje F. Oosting, Robert I. Haddad |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
squamous cell carcinoma
0301 basic medicine Cancer Research medicine.medical_specialty medicine.medical_treatment best practice INVESTIGATORS CHOICE Review chemotherapy lcsh:RC254-282 Systemic therapy law.invention ADVANCED LARYNX 03 medical and health sciences WEEKLY CISPLATIN 0302 clinical medicine Quality of life (healthcare) Randomized controlled trial QUALITY-OF-LIFE law PERCUTANEOUS ENDOSCOPIC GASTROSTOMY RADIATION-THERAPY medicine Intensive care medicine AMERICAN SOCIETY business.industry Head and neck cancer Induction chemotherapy systemic treatment lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Head and neck squamous-cell carcinoma RANDOMIZED-TRIAL Radiation therapy 030104 developmental biology Oncology 030220 oncology & carcinogenesis PHASE-II head and neck cancer Patient-reported outcome immunotherapy LOCALLY ADVANCED HEAD business |
| Zdroj: | Frontiers in Oncology, Vol 9 (2019) Frontiers in Oncology |
| ISSN: | 2234-943X |
| Popis: | Treating head and neck cancer patients with systemic therapy is challenging because of tumor related, patient related and treatment related factors. In this review, we aim to summarize the current standard of care in the curative and palliative setting, and to describe best practice with regard to structural requirements, procedures, and monitoring outcome. Treatment advice for individual head and neck cancer patients is best discussed within a multidisciplinary team. Cisplatin is the drug of choice for concomitant chemoradiotherapy in the primary and postoperative setting, and also a main component of induction chemotherapy. However, acute and late toxicity is often significant. Checkpoint inhibitors have recently been proven to be active in the metastatic setting which has resulted in a shift of paradigm. Detailed knowledge, institution of preventive measures, early recognition, and prompt treatment of adverse events during systemic therapy is of paramount importance. Documentation of patient characteristics, tumor characteristics, treatment details, and clinical and patient reported outcome is essential for monitoring the quality of care. Participation in initiatives for accreditation and registries for benchmarking institutional results are powerful incentives for implementation of best practice procedures. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|